SUNFISH is a 2-part, placebo-controlled study in people with Type 2 or 3 spinal muscular atrophy (SMA). The trial included people 2 to 25 years: the first placebo-controlled trial in adults and children older than 9 years of age with SMA.
Change in motor function score over 1 year vs placebo
As measured by MFM-32
*In some studies, including this one, if someone’s data cannot be collected on time for any reason, that person’s progress cannot be counted in that part of the study. This chart includes only the information that was collected on time.
†Adults and children not taking Evrysdi took a placebo, a substance that has no active medication and is often used in studies.
‡This 95% CI (confidence interval) means that we are 95% confident that the actual average change in MFM-32 with Evrysdi will be between 0.30 and 2.81 points higher than with placebo.
MFM-32 stands for Motor Function Measure-32 Items. NA stands for not applicable.
The Motor Function Measure-32 Items (MFM-32) scale measures motor function abilities that relate to important daily functions. It evaluates 32 different elements to assess motor movement across 3 categories:
Standing/transfer movements
Upper/lower body movements
Hand/foot movements
The scale is designed to capture change for a broad range of people, including those who can and cannot walk.
1.83-point average change in MFM-32 score from the start of the study with Evrysdi.
This information is considered exploratory, which means the clinical trial was not specifically designed to demonstrate that Evrysdi caused these results. Data should be interpreted with caution.
*In some studies, including this one, if someone’s data cannot be collected on time for any reason, that person’s progress cannot be counted in that part of the study. This chart includes only the information that was collected on time.
†Adults and children not taking Evrysdi took a placebo, a substance that has no active medication and is often used in studies. People in this group received placebo for 12 months followed by Evrysdi for 12 months. The period of time on Evrysdi is not included in this chart. The follow-up period was not placebo controlled.
MFM-32 stands for Motor Function Measure-32 Items. NA stands for not applicable.
“Since starting Evrysdi, I have noticed changes in my motor function. I can better push up on my arms and stand when transferring out of my wheelchair.”
*In some studies, including this one, if someone’s data cannot be collected on time for any reason, that person’s progress cannot be counted in that part of the study. This chart includes only the information that was collected on time.
†Adults and children not taking Evrysdi took a placebo, a substance that has no active medication and is often used in studies.
‡This 95% CI (confidence interval) means that we are 95% confident that the actual average change in RULM with Evrysdi will be between 0.55 and 2.62 points higher than with placebo.
RULM stands for Revised Upper Limb Module assessment. NA stands for not applicable.
The Revised Upper Limb Module (RULM) evaluates strength in arm movements and the ability to perform specific tasks. It was specifically designed for people 2.5 years and older living with SMA who have varying levels of muscle weakness and includes tests such as:
*Weight is approximate and has been converted from grams to pounds.
2.79-point average change in RULM score from the start of the study with Evrysdi.
This information is considered exploratory, which means the clinical trial was not specifically designed to demonstrate that Evrysdi caused these results. Data should be interpreted with caution.
*In some studies, including this one, if someone’s data cannot be collected on time for any reason, that person’s progress cannot be counted in that part of the study. This chart includes only the information that was collected on time.
†Adults and children not taking Evrysdi took a placebo, a substance that has no active medication and is often used in studies. People in this group received placebo for 12 months followed by Evrysdi for 12 months. The period of time on Evrysdi is not included in this chart. The follow-up period was not placebo controlled.
RULM stands for Revised Upper Limb Module assessment. NA stands for not applicable.
My goal was to maintain the strength I had and hopefully slow the progression. Since Evrysdi, I have had improvements in my physical assessments and I’m better able to hold my pen and write more consistently.”
We can help
Hear community perspectives
Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.
Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.